Literature DB >> 21226988

Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.

M Tumbarello1, E Repetto, E M Trecarichi, C Bernardini, G De Pascale, A Parisini, M Rossi, M P Molinari, T Spanu, C Viscoli, R Cauda, M Bassetti.   

Abstract

We retrospectively studied patients diagnosed with P. aeruginosa bloodstream infections (BSIs) in two Italian university hospitals. Risk factors for the isolation of multidrug-resistant (MDR) or non-MDR P. aeruginosa in blood cultures were identified by a case-case-control study, and a cohort study evaluated the clinical outcomes of such infections. We identified 106 patients with P. aeruginosa BSI over the 2-year study period; 40 cases with MDR P. aeruginosa and 66 cases with non-MDR P. aeruginosa were compared to 212 controls. Independent risk factors for the isolation of MDR P. aeruginosa were: presence of central venous catheter (CVC), previous antibiotic therapy, and corticosteroid therapy. Independent risk factors for non-MDR P. aeruginosa were: previous BSI, neutrophil count <500/mm3, urinary catheterization, and presence of CVC. The 21-day mortality rate of all patients was 33·9%. The variables independently associated with 21-day mortality were presentation with septic shock, infection due to MDR P. aeruginosa, and inadequate initial antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21226988     DOI: 10.1017/S0950268810003055

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  32 in total

1.  Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.

Authors:  Bianca Dößelmann; Matthias Willmann; Matthias Steglich; Boyke Bunk; Ulrich Nübel; Silke Peter; Richard A Neher
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

3.  IRF3 Inhibits Neutrophil Recruitment in Mice Infected with Pseudomonas aeruginosa.

Authors:  Zhenghao Piao; Haiying Yuan; Cuili Wang; Liyun Shi
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

Review 4.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

5.  Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007-2015).

Authors:  Giulia De Angelis; Barbara Fiori; Giulia Menchinelli; Tiziana D'Inzeo; Flora Marzia Liotti; Grazia Angela Morandotti; Maurizio Sanguinetti; Brunella Posteraro; Teresa Spanu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-09       Impact factor: 3.267

6.  Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Barbara Fiori; Angela Raffaella Losito; Tiziana D'Inzeo; Lara Campana; Alberto Ruggeri; Eugenia Di Meco; Elvira Liberto; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

7.  Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.

Authors:  C Peña; S Gómez-Zorrilla; C Suarez; M A Dominguez; F Tubau; O Arch; A Oliver; M Pujol; J Ariza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-04       Impact factor: 3.267

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 9.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.

Authors:  Mario Tumbarello; Gennaro De Pascale; Enrico Maria Trecarichi; Teresa Spanu; Federica Antonicelli; Riccardo Maviglia; Mariano Alberto Pennisi; Giuseppe Bello; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2013-02-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.